Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF‐targeted therapies. (25th July 2015) - Patel, Gargi S.
Abstract This is one of only a handful of studies examining the prognostic and predictive capacity of body mass index (BMI) in mCRC patients. The BMI is predictive of a poorer outcome for underweight and overweight patients in the whole population. Of those receiving chemotherapy and targeted therapy, a raised BMI is an independent predictor for poorer overall survival for overweight and obese I patients, specifically for Bevacizumab. We highlight a potential area for optimization of expensive targeted therapies with lifestyle and nutritional interventions, for up to 60% of the population.